FosteraTM PRRS modified live vaccine efficacy against a Canadian heterologous virulent field strain of porcine reproductive and respiratory syndrome virus (PRRSV).
Series/Report no.Canadian Journal of Veterinary Research;Vol. 80, no 1
Vaccination is a useful option to control infection with porcine reproductive and respiratory syndrome virus (PRRSV), and several modified live-PRRSV vaccines have been developed. These vaccines have shown some efficacy in reducing the incidence and severity of clinical disease as well as the duration of viremia and virus shedding but have failed to provide sterilizing immunity. The efficacy of modified live-virus (MLV) vaccines is greater against a homologous strain compared with heterologous PRRSV strains. The objective of this study was to evaluate the efficacy of Fostera PRRS MLV vaccine in protecting against challenge with a heterologous field strain widely circulating in the swine herds of eastern Canada. Forty-six piglets were divided into 4 groups: nonvaccinated-nonchallenged; nonvaccinated-challenged; vaccinated-challenged; and vaccinated-nonchallenged. The animals were vaccinated at 23 d of age with Fostera PRRS and challenged 23 d later with a heterologous field strain of PRRSV (FMV12-1425619). Overall, the vaccine showed some beneficial effects in the challenged animals by reducing the severity of clinical signs and the viral load. A significant difference between nonvaccinated and vaccinated animals was detected for some parameters starting 11 to 13 d after challenge, which suggested that the cell-mediated immune response or other delayed responses could be more important than pre-existing PRRSV antibodies in vaccinated animals within the context of protection against heterologous strains.
C. Savard, F. Alvarez, C. Provost, Y. Chorfi, S. D’Allaire, M.-O. Benoit-Biancamano, C.A. Gagnon. FosteraTM PRRS modified live vaccine efficacy against a Canadian heterologous virulent field strain of porcine reproductive and respiratory syndrome virus (PRRSV). Can J Vet Res 2016; 80(1):1-11.